DK4043460T3 - Antiproliferationsforbindelser og anvendelser deraf - Google Patents

Antiproliferationsforbindelser og anvendelser deraf Download PDF

Info

Publication number
DK4043460T3
DK4043460T3 DK22161962.0T DK22161962T DK4043460T3 DK 4043460 T3 DK4043460 T3 DK 4043460T3 DK 22161962 T DK22161962 T DK 22161962T DK 4043460 T3 DK4043460 T3 DK 4043460T3
Authority
DK
Denmark
Prior art keywords
antiproliferative compounds
antiproliferative
compounds
Prior art date
Application number
DK22161962.0T
Other languages
English (en)
Inventor
Shashank Kulkarni
Henry Yu
Michael Clark
Guy Bemis
Michael Boyd
Kishan Chandupatla
Philip Collier
Hongbo Deng
Huijun Dong
Warren Dorsch
Russell R Hoover
Mac Arthur Johnson Jr
Marina Penney
Steven Ronkin
Darin Takemoto
Qing Tang
Nathan D Waal
Tiansheng Wang
David J Lauffer
Pan Li
Original Assignee
Merck Patent Gmbh
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Vertex Pharma filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK4043460T3 publication Critical patent/DK4043460T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK22161962.0T 2018-04-24 2019-04-23 Antiproliferationsforbindelser og anvendelser deraf DK4043460T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661719P 2018-04-24 2018-04-24
EP19726792.5A EP3784666B1 (en) 2018-04-24 2019-04-23 Antiproliferation compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK4043460T3 true DK4043460T3 (da) 2024-08-26

Family

ID=66655429

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19726792.5T DK3784666T3 (da) 2018-04-24 2019-04-23 Antiproliferationsforbindelser og anvendelser deraf
DK22161962.0T DK4043460T3 (da) 2018-04-24 2019-04-23 Antiproliferationsforbindelser og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19726792.5T DK3784666T3 (da) 2018-04-24 2019-04-23 Antiproliferationsforbindelser og anvendelser deraf

Country Status (27)

Country Link
US (4) US10815225B2 (da)
EP (2) EP3784666B1 (da)
JP (2) JP7304892B2 (da)
KR (1) KR102813581B1 (da)
CN (1) CN112236428B (da)
AR (1) AR114496A1 (da)
AU (1) AU2019261308B2 (da)
BR (1) BR112020020940A2 (da)
CA (1) CA3098335A1 (da)
CY (1) CY1125433T1 (da)
DK (2) DK3784666T3 (da)
ES (2) ES2987356T3 (da)
FI (1) FI4043460T3 (da)
HR (2) HRP20241163T1 (da)
HU (2) HUE067936T2 (da)
IL (2) IL278142B2 (da)
LT (1) LT3784666T (da)
MX (1) MX2020011089A (da)
PL (2) PL4043460T3 (da)
PT (2) PT3784666T (da)
RS (1) RS63281B1 (da)
SG (1) SG11202009500QA (da)
SI (1) SI3784666T1 (da)
SM (1) SMT202200308T1 (da)
TW (1) TWI813673B (da)
WO (1) WO2019209759A1 (da)
ZA (1) ZA202006071B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3784666T3 (da) 2018-04-24 2022-06-20 Merck Patent Gmbh Antiproliferationsforbindelser og anvendelser deraf
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020236834A1 (en) * 2019-05-20 2020-11-26 Seshadri Raju Modified z stents for iliac vein stenting
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
US20240132464A1 (en) * 2022-09-28 2024-04-25 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
WO2025223536A1 (zh) * 2024-04-26 2025-10-30 正大天晴药业集团股份有限公司 稠合双环化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE19840028A1 (de) 1998-09-02 2000-03-09 Max Planck Gesellschaft Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-d] 피리미딘 화합물
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7071189B2 (en) 2001-04-27 2006-07-04 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
BRPI0313733A8 (pt) 2002-08-14 2016-08-16 Atugen Ag Uso da proteína n beta cinase
EA012240B1 (ru) 2003-04-03 2009-08-28 Семафор Фармасьютикалз, Инк. Пролекарства ингибиторов киназы pi-3
EP1644363B1 (en) 2003-05-30 2012-02-22 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods for treating cancer
JP2007524397A (ja) 2003-07-03 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア Sykキナーゼ発現の阻害
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
JP4801096B2 (ja) 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
WO2007040650A2 (en) 2005-05-12 2007-04-12 Abbott Laboratories Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
SI1931645T1 (sl) 2005-10-07 2014-09-30 Exelixis, Inc. N-(3-amino-kvinoksalin-2-YL)-sulfonamid-derivati in uporaba le teh kot fosfatidilinositol-3-kinaze-inhibitorji
RU2589878C2 (ru) 2005-11-01 2016-07-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
PT2348023E (pt) 2005-12-13 2015-09-15 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP5148597B2 (ja) 2006-04-26 2013-02-20 エフ.ホフマン−ラ ロシュ アーゲー 医薬化合物
PT2530083T (pt) 2006-09-22 2016-08-01 Pharmacyclics Llc Inibidores de tirosina cinase de bruton
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
BRPI0808888B8 (pt) 2007-03-12 2021-05-25 Cytopia Res Pty Ltd composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
SI2288610T1 (sl) 2008-03-11 2016-11-30 Incyte Holdings Corporation Derivati azetidina in ciklobutana kot inhibitorji jak
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
JP2011529920A (ja) 2008-07-31 2011-12-15 ジェネンテック, インコーポレイテッド ピリミジン化合物、組成物及び使用方法
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
MX2012005596A (es) * 2009-12-04 2012-05-29 Hoffmann La Roche Derivados de difenil azepano como inhibidores de reabsorcion de monoaminas.
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107207482A (zh) 2015-02-13 2017-09-26 默克专利股份公司 用于治疗癌症的嘧啶衍生物
DK3784666T3 (da) 2018-04-24 2022-06-20 Merck Patent Gmbh Antiproliferationsforbindelser og anvendelser deraf

Also Published As

Publication number Publication date
ES2987356T3 (es) 2024-11-14
DK3784666T3 (da) 2022-06-20
US20190322658A1 (en) 2019-10-24
US20230150993A1 (en) 2023-05-18
AU2019261308B2 (en) 2022-09-08
AR114496A1 (es) 2020-09-09
HUE067936T2 (hu) 2024-11-28
KR102813581B1 (ko) 2025-05-29
HRP20241163T1 (hr) 2024-11-22
TW202012400A (zh) 2020-04-01
PL4043460T3 (pl) 2024-10-28
CN112236428A (zh) 2021-01-15
SI3784666T1 (sl) 2022-07-29
ZA202006071B (en) 2024-01-31
JP2023101824A (ja) 2023-07-21
WO2019209759A1 (en) 2019-10-31
US12195453B2 (en) 2025-01-14
HRP20220710T1 (hr) 2022-07-22
CA3098335A1 (en) 2019-10-31
RS63281B1 (sr) 2022-06-30
PT4043460T (pt) 2024-09-10
JP2021522242A (ja) 2021-08-30
SMT202200308T1 (it) 2022-09-14
KR20210005151A (ko) 2021-01-13
IL278142B1 (en) 2023-07-01
BR112020020940A2 (pt) 2021-03-02
EP3784666A1 (en) 2021-03-03
IL301501A (en) 2023-05-01
PL3784666T3 (pl) 2022-07-18
CY1125433T1 (el) 2025-05-09
EP4043460A1 (en) 2022-08-17
JP7304892B2 (ja) 2023-07-07
EP3784666B1 (en) 2022-03-16
FI4043460T3 (fi) 2025-05-09
IL301501B1 (en) 2024-06-01
IL301501B2 (en) 2024-10-01
SG11202009500QA (en) 2020-11-27
AU2019261308A1 (en) 2020-10-22
TWI813673B (zh) 2023-09-01
IL278142B2 (en) 2023-11-01
LT3784666T (lt) 2022-06-10
IL278142A (en) 2020-11-30
US10815225B2 (en) 2020-10-27
US20250188070A1 (en) 2025-06-12
HUE058746T2 (hu) 2022-09-28
CN112236428B (zh) 2025-04-01
EP4043460B1 (en) 2024-06-05
US11440907B1 (en) 2022-09-13
ES2919572T3 (es) 2022-07-27
MX2020011089A (es) 2020-11-06
PT3784666T (pt) 2022-06-06

Similar Documents

Publication Publication Date Title
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3946464T3 (da) Forbindelser og konjugater deraf
IL282998A (en) Pyridazinone compounds and uses thereof
IL285461A (en) Processes and compounds
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3784283T3 (da) Cannabidiopræparater og anvendelser deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
IL278122B1 (en) Pteridinone compounds and uses thereof
DK3658148T3 (da) Makrocykliske forbindelser og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3596125T3 (da) Anti-PAR2-antistoffer og anvendelser deraf
DK3784666T3 (da) Antiproliferationsforbindelser og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3399978T3 (da) Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
EP3893945A4 (en) CROMOGLYC ESTERS AND THEIR USES
DK3813946T3 (da) Rapamycin-analoger og anvendelser deraf
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3743106T3 (da) Influenzavirusvacciner og anvendelser deraf
DK3612579T3 (da) Pultrudat, fremstilling og anvendelse heraf
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf
DK3653613T3 (da) 1,3-disubstitueret ketenforbindelse og anvendelse deraf